Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
Researchers are evaluating the effects of cemsidomide combined with dexamethasone in people with relapsed or refractory multiple myeloma, a type of blood cancer. This Phase 2, open-label, single-arm, multicenter study aims to understand the treatments ability to fight the disease as well as its safety, how it is processed in the body, and how it affects the body over time. Participants will take cemsidomide orally once daily for 14 days followed by 14 days off in each 28-day treatment cycle, along with dexamethasone taken orally once a week on days 1, 8, 15, and 22 of each cycle. Treatment continues until certain stopping criteria are met. This study involves only one treatment group receiving this combination. Throughout the study, participants will be monitored regularly for response to treatment, including overall response rate, duration and time to response, progression-free survival, and overall survival, with assessments lasting up to around 43 months. Safety is closely tracked by recording any adverse events during and shortly after treatment. Blood samples will be collected to measure cemsidomide levels during the first four months. Participants remain in the study for ongoing evaluation until study completion.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of nemtabrutinib in adults with various blood cancers including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, Richters transformation, marginal zone lymphoma MZL, mantle cell lymphoma MCL, follicular lymphoma FL, and Waldenstrms macroglobulinemia WM. This phase 2 study is sponsored by Merck Sharp & Dohme LLC and involves two parts Dose Escalation and Confirmation Part 1 and Cohort Expansion Part 2, which includes eight disease-specific groups. Participants receive nemtabrutinib tablets orally once daily until their disease progresses or they discontinue the treatment. Part 1 focuses on finding the recommended dose and assessing safety, while Part 2 enrolls participants in specific cohorts based on their disease type and treatment history. Cohorts include various lymphoma and leukemia subtypes, with some requiring prior therapy history and measurable disease criteria. During the study, participants will be monitored regularly for side effects, disease response, and drug levels in the body. Assessments include imaging scans, biopsies, blood tests, and evaluations based on established lymphoma and leukemia criteria. The study measures outcomes such as dose-limiting toxicities, adverse events, treatment discontinuations, and objective response rates over periods ranging from weeks to several years. Participants may stay in the study for up to approximately 5 years, with ongoing monitoring to evaluate the treatments impact and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sapablursen when added to the current standard of care for treating Polycythemia Vera PV. This Phase 3 trial involves participants who depend on phlebotomy and meet specific diagnostic criteria for PV. The study aims to assess how well sapablursen controls the need for phlebotomy and other health measures in this condition. The study has three parts Part 1a is a 32-week period where participants receive either sapablursen or a placebo in a double-blind manner. In Part 1b, participants receive open-label sapablursen for 124 weeks following the initial phase. There is also a long-term extension phase allowing treatment for up to 156 weeks. Sapablursen and placebo are given by subcutaneous injection. Participants will undergo various assessments, including monitoring of hematocrit levels, number of phlebotomies, and patient-reported symptoms such as fatigue and myelofibrosis symptoms. The main outcome is the percentage of participants who do not need phlebotomy between weeks 20 and 32. Safety and effectiveness are followed throughout the study, which may last up to nearly five years from start to completion.
Actively Recruiting
Researchers are evaluating whether 225Ac-PSMA-617 AAA817 combined with androgen receptor pathway inhibitors ARPI prolongs radiographic progression-free survival rPFS compared to standard treatments in adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study focuses on participants who have previously been treated with ARPI but not taxane chemotherapy or prior PSMA-targeting radioligand therapy in the mCRPC setting. This phase III, open-label, randomized study is conducted globally including the USA. Participants are randomly assigned to receive either up to six intravenous doses of AAA817 at 10 Megabecquerel MBq plus oral ARPI enzalutamide or abiraterone, or one of the standard care options chosen by investigators. Standard care options include switching ARPI, taxane-based chemotherapy docetaxel or cabazitaxel, or 177Lu-PSMA-617 AAA617 radioligand therapy. Treatment with ARPI continues per protocol until defined end of treatment criteria. Supportive care including androgen deprivation therapy is allowed in both groups. Crossover between groups is not permitted. Participants undergo screening to confirm eligibility including PSMA-positive status via PETCT scans. Throughout the study, safety assessments are performed regularly. Researchers will measure outcomes including radiographic progression-free survival up to approximately 40 months after randomization, as well as overall survival and other cancer progression markers. The study also monitors treatment responses, pain levels, and quality of life measures. Participants remain under observation for the duration of the study until the end date in 2032.
Actively Recruiting
Researchers are studying whether adding navtemadlin to ruxolitinib treatment can provide more benefit than ruxolitinib alone for adults with Myelofibrosis who have not responded well to ruxolitinib by itself. This Phase 3 trial includes patients who are new to JAK inhibitor treatment and have a confirmed diagnosis of primary or post-polycythemia vera or post-essential thrombocythemia Myelofibrosis. The study aims to assess improvements in spleen size and symptom reduction over 24 weeks, as well as long-term outcomes like disease progression and overall survival. Participants first receive ruxolitinib alone during a run-in period to identify those with suboptimal response. Those qualifying are randomly assigned in a 21 ratio to receive either navtemadlin or a placebo as an add-on to their ongoing ruxolitinib. Navtemadlin or placebo is taken orally once daily for 7 days followed by 21 days off in 28-day cycles, while ruxolitinib is taken twice daily continuously. The study is double-blinded so neither participants nor researchers know which add-on treatment is given. During the trial, participants will undergo evaluations including spleen volume measurements and symptom assessments at 24 weeks. They will be monitored for disease progression and survival for up to 8 years. The study includes regular check-ups to track side effects, treatment adherence, and overall health status. These detailed assessments help researchers understand the potential benefits and safety of adding navtemadlin for patients with Myelofibrosis.
Actively Recruiting
Researchers are studying metastatic castration-resistant prostate cancer in men who have progressed after treatment with androgen receptor pathway inhibitors. The study aims to compare the length of time patients live without their cancer worsening on imaging when treated with 177Lu-TLX591 plus standard care versus standard care alone. This is a Phase 3 trial with a focus on both efficacy and safety of the new treatment in this patient group. Participants are divided into three parts a safety and dosimetry lead-in with 30 patients, a randomized treatment expansion with approximately 490 patients, and a long-term follow-up period lasting at least 5 years. In the randomized phase, patients receive either 177Lu-TLX591 plus standard of care, which may include enzalutamide, abiraterone, or docetaxel, or standard of care alone. The 177Lu-TLX591 is given as two doses about 14 days apart. Standard care treatments involve oral medications or chemotherapy as specified. During the study, participants will be regularly monitored through scans and other assessments to evaluate cancer progression and safety. Imaging includes PETCT or PETMRI scans to confirm PSMA positivity and detect disease spread. Researchers will track radiographic progression-free survival as the main outcome, along with overall survival and response rates. The long-term follow-up helps assess lasting effects and safety over several years. Participants are expected to adhere to study protocols and radiation safety precautions throughout their involvement.